- Market Capitalization, $K 186,924,288
- Shares Outstanding, K 2,236,739
- Annual Sales, $ 49,898 M
- Annual Income, $ 8,072 M
- 60-Month Beta 0.54
- Price/Sales 3.81
- Price/Cash Flow 10.85
- Price/Book 3.78
|Period||Period Low||Period High||Performance|
| || |
-9.22 (-10.01%)since 08/24/21
| || |
-9.53 (-10.31%)since 06/24/21
| || |
-3.37 (-3.90%)since 09/24/20
FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.
Health care company Merck & Co’s (MRK) shares have declined more than 8% in price over the past month. However, the company made several advancements and reported impressive top-line growth across its...
Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.
The Zacks Analyst Blog Highlights: Facebook, Walmart, Novartis, PayPal and Advanced Micro Devices
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), Walmart Inc. (WMT), and Novartis AG (NVS).
Research Nester published a report titled which delivers detailed overview of the global immunotherapy drugs market in terms of market segmentation by type, therapy area, and by region.
/PRNewswire/ -- Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali (ribociclib) in combination with letrozole compared...
The FDA grants accelerated nod to BeiGene's (BGNE) Brukinsa for treating adults with relapsed or refractory marginal zone lymphoma. This marks the third approval for the drug in the United States.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2029" which delivers detailed overview of the global ophthalmology equipment market in terms of market segmentation...
|Novartis Ag ADR|
|Vaneck Pharmaceutical ETF|
|Intl Dividend Achievers Invesco ETF|
|Pacer Global Cash Cows Dividend ETF|
|Pacer Military Times Best Employers ETF|
|Pacer Trendpilot International ETF|
|3rd Resistance Point||84.20|
|2nd Resistance Point||83.94|
|1st Resistance Point||83.43|
|1st Support Level||82.66|
|2nd Support Level||82.40|
|3rd Support Level||81.89|